LMP517 is a potent dual inhibitor of topoisomerase I (TOP1) and topoisomerase II (TOP2); it exhibits enhanced antitumor activity against H82 (small cell lung cancer) xenografts compared to its parent compound LMP744; it induces TOP1 cleavage complexes (TOP1ccs) and TOP2 cleavage complexes (TOP2ccs).